Trial Profile
A Phase I Trial of Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no Concurrent BRAFV600 Mutations) Melanoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Ulixertinib (Primary)
- Indications Cholangiocarcinoma; Gastrointestinal stromal tumours; Malignant melanoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 18 Nov 2022 Status changed from active, no longer recruiting to recruiting.
- 08 Nov 2022 Planned End Date changed from 24 Oct 2023 to 24 Apr 2026.
- 08 Nov 2022 Planned primary completion date changed from 24 Oct 2022 to 15 Jul 2024.